Myeloproliferative Disorders
"Myeloproliferative Disorders" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.
| Descriptor ID |
D009196
|
| MeSH Number(s) |
C15.378.190.636
|
| Concept/Terms |
Myeloproliferative Disorders- Myeloproliferative Disorders
- Disorder, Myeloproliferative
- Disorders, Myeloproliferative
- Myeloproliferative Disorder
|
Below are MeSH descriptors whose meaning is more general than "Myeloproliferative Disorders".
Below are MeSH descriptors whose meaning is more specific than "Myeloproliferative Disorders".
This graph shows the total number of publications written about "Myeloproliferative Disorders" by people in this website by year, and whether "Myeloproliferative Disorders" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 3 | 1 | 4 |
| 2004 | 1 | 0 | 1 |
| 2006 | 1 | 0 | 1 |
| 2007 | 4 | 1 | 5 |
| 2009 | 5 | 0 | 5 |
| 2010 | 2 | 0 | 2 |
| 2011 | 3 | 0 | 3 |
| 2012 | 1 | 0 | 1 |
| 2013 | 2 | 0 | 2 |
| 2014 | 3 | 0 | 3 |
| 2015 | 2 | 0 | 2 |
| 2016 | 3 | 1 | 4 |
| 2017 | 2 | 1 | 3 |
| 2018 | 2 | 0 | 2 |
| 2019 | 2 | 0 | 2 |
| 2020 | 4 | 0 | 4 |
| 2021 | 1 | 1 | 2 |
| 2022 | 16 | 0 | 16 |
| 2023 | 14 | 0 | 14 |
| 2024 | 7 | 3 | 10 |
| 2025 | 9 | 0 | 9 |
| 2026 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Myeloproliferative Disorders" by people in Profiles.
-
Impact of statin use on cardiovascular and hematologic outcomes among patients with myeloproliferative neoplasms. Blood Adv. 2026 Mar 10; 10(5):1603-1613.
-
Contemporary data in myeloproliferative neoplasm-unclassifiable: mutational landscape and management of the 'unclassifiable'. Curr Opin Hematol. 2026 Mar 01; 33(2):45-50.
-
Type 2 calreticulin mutations activate ATF6 to promote BCL-xL-mediated survival in myeloproliferative neoplasms. Blood. 2025 Aug 21; 146(8):971-983.
-
Factors associated with survival after allogeneic transplantation for myeloid neoplasms harboring TP53 mutations. Blood Adv. 2025 Jul 22; 9(14):3395-3407.
-
Role of allo-HCT in "nonclassical" MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT. Blood. 2025 May 29; 145(22):2561-2573.
-
Multihit TP53 Mutations in Myeloproliferative Neoplasms and Acute Myeloid Leukemia: Comparative Analysis of Survival and Risk Factors in 142 Informative Cases. Am J Hematol. 2025 Jun; 100(6):1010-1018.
-
Classification of Myelodysplastic, Myeloproliferative, and Myelodysplastic/Myeloproliferative Neoplasms: The Past, Present, and Future. Am J Hematol. 2025 Jun; 100 Suppl 4:5-15.
-
Evolution of WHO diagnostic criteria in "Classical Myeloproliferative Neoplasms" compared with the International Consensus Classification. Blood Cancer J. 2025 03 04; 15(1):31.
-
SOHO State of the Art Updates and Next Questions | Challenging Scenarios in the Management of Myeloproliferative Neoplasms. Clin Lymphoma Myeloma Leuk. 2025 Jul; 25(7):484-493.
-
TP53 Mutations in Myeloproliferative Neoplasms: Context-Dependent Evaluation of Prognostic Relevance. Am J Hematol. 2025 Apr; 100(4):552-560.